#None #NASDAQ #medical cannabis #IM Cannabis

IM Cannabis Corp. Trading Update

On August 27, 2026, IM Cannabis Corp. (traded as IMCC on Nasdaq) announced the commencement of trading on a 30-for-1 consolidated basis, following their recent consolidation strategy. The decision comes after an earlier press release that hinted at changes aimed at improving market performance amid current trading conditions. This action reflects the company’s strong commitment to optimizing its operations within the medical cannabis industry, specifically focusing on their existing markets in Israel and Germany.

The share consolidation process has led to the reduction of total common shares from a substantial 18,567,650 down to approximately 618,899 shares. This strategic move aims to streamline the company’s share structure, and the existing trading symbol 'IMCC' will remain unchanged. Furthermore, the updated CUSIP and ISIN numbers are 44969Q505 and CA44969Q5059, respectively, which will help in differentiating the post-consolidation shares from those that existed prior to the process.

According to the company's statements, the consolidation is anticipated to improve the trading price of IMCC’s shares, aligning them with Nasdaq's minimum required bid price of $1.00. This move is essential not only for maintaining the listing but also for enhancing shareholder value. The management highlighted the potential benefits of this consolidation in their investor reports, emphasizing its importance in light of the current economic landscape and the competitive nature of the medical cannabis market.

Computershare Investor Services Inc., the registrar for IM Cannabis, has been proactive in communicating with shareholders regarding the consolidation process. All registered shareholders as of the consolidation date have been sent letters with instructions on how to exchange their previous share certificates for new ones reflecting the consolidated share count. Following the consolidation, all fractions of a share resulting from this process have either been rounded up or canceled, ensuring a neat transition into the new share structure. Beneficial holders—those who own shares through intermediaries—are advised to maintain close contact with their brokers to ensure a smooth exchange process as outlined by the company’s communications.

IM Cannabis Corp. is recognized for its robust operations in the medical cannabis space, touching upon both importation and distribution across its focused territories. With a comprehensive platform catering to medical patients in Israel, as well as distributing cannabis through partnerships with pharmacies in Germany, IMC appears poised to capitalize on growing market demands, leveraging substantial innovations in their operational strategies. Furthermore, the company is exploring avenues for expansion into technology-driven sectors, indicating a forward-thinking approach in diversifying their service offerings.

Looking ahead, the consolidation is merely a stepping stone for IM Cannabis Corp. as they strive for enhanced compliance with market regulations and aim to foster a resilient business model in an ever-evolving industry. Projections and forward-looking statements concerning the company’s market performance will be closely monitored, particularly in relation to compliance with Nasdaq listing requirements in the future.

As IM Cannabis continues to navigate the complexities of the global cannabis landscape, its adaptive strategies and commitment to innovation will be pivotal in its pursuit of growth and sustainability. Expectations are high for how these recent developments will influence market perceptions and shareholder engagement moving forward.